Health Economics›Small cell lung cancer›Relapsed or refractory disease subsequent lines

Relapsed or refractory disease subsequent lines

Small cell lung cancer · 15 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Epirubicin and Ifosfamide Variant #03	—	R 27 949	21d	—	—	~7	~R 195 643 indirect	—
Topotecan monotherapy Variant #01	—	R 18 138	21d	2.7 mo	8.3 mo	11	R 199 522 PFS proxy	8
Ifosfamide and Paclitaxel Variant #01	—	R 9 725	21d	—	~21.3 mo	~10	~R 97 251 PFS proxy · indirect	2
Ifosfamide monotherapy Variant #05	—	R 8 704	21d	~4.0 mo	~8.4 mo	~8	~R 69 635 PFS proxy · indirect	2
Temozolomide monotherapy Variant #02	—	R 7 358	14d	~4.0 mo	~16.3 mo	~26	~R 129 994 PFS proxy · indirect	10
Bendamustine monotherapy Variant #01	—	R 7 084	—	~16.5 mo	—	~6	~R 42 504 PFS proxy · indirect	2
Docetaxel monotherapy Variant #02	—	R 2 921	28d	~3.2 mo	~9.8 mo	~7	~R 20 450 PFS proxy · indirect	52
Irinotecan monotherapy Variant #01	—	R 2 716	42d	—	7.0 mo	11	R 29 874 PFS proxy	—
Cisplatin and Etoposide (EP) Variant #22	—	R 1 819	21d	~5.0 mo	~10.2 mo	~4	~R 7 277 PFS proxy · indirect	10
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	~3.8 mo	~6.6 mo	~7	~R 11 705 PFS proxy · indirect	7
Etoposide monotherapy Variant #01	—	R 1 231	28d	—	—	~6	~R 7 386 indirect	—
CAV Variant #06	—	R 865	21d	—	7.6 mo	6	R 5 188 PFS proxy	1
Paclitaxel monotherapy Variant #02	—	R 734	28d	—	~6.8 mo	~7	~R 5 141 PFS proxy · indirect	2
Vinorelbine monotherapy Variant #01	—	R 458	21d	—	~6.3 mo	~12	~R 5 490 PFS proxy · indirect	4
Tarlatamab monotherapy Variant #01 Partial	—	—	14d	—	13.6 mo	2	—	—

15 of 15 regimens shown